RFK Jr. Aims to Slash Big Pharma Revenue Under Trump Plan

---

Full Story

Secretary RFK Jr. announced a plan to reduce U.S. contributions to global pharmaceutical revenues, currently at 75% despite the U.S. having only 4% of the world’s population. The Trump administration aims to lower drug prices to European levels. The policy targets Big Pharma’s pricing practices.

RFK Jr. highlighted the $1,300 U.S. price for Ozempic. In London, the same drug costs $88.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 30% | Right 35% | Center 26% | Unrated 9%

The Context

The plan includes escalating steps to enforce compliance. Drug companies face pressure to cooperate.

High U.S. drug prices have long been a bipartisan issue. Past efforts to address them stalled.

RFK Jr. claims pharmaceutical firms acknowledge the disparity. Meetings with companies are ongoing.

The policy seeks to align U.S. prices with global standards. Implementation depends on industry cooperation.

Supporters praise the plan for tackling costs. Critics warn of potential innovation slowdowns.

Some favor lower prices for affordability. Others fear reduced drug development funding.